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Abstract
Background Patient preferences (PP), which are investigated in PP studies using qualitative or quantitative methods, are a 
growing area of interest to the following stakeholders involved in the medical product lifecycle: academics, health technol-
ogy assessment bodies, payers, industry, patients, physicians, and regulators. However, the use of PP in decisions along the 
medical product lifecycle remains limited. As the adoption of PP heavily relies on these stakeholders, knowledge of their 
perceptions of PP is critical.
Objective This study aimed to characterize stakeholders’ attitudes, needs, and concerns with respect to PP in decision mak-
ing along the medical product lifecycle.
Methods Semi-structured interviews (n = 143) were conducted with academics (n = 24), health technology assessment/
payer representatives (n = 24), industry representatives (n = 24), patients, caregivers and patient representatives (n = 24), 
physicians (n = 24), and regulators (n = 23) from seven European countries and the USA. Interviews were conducted between 
April and August 2017. The framework method was used to organize the data and identify themes and key findings in each 
interviewed stakeholder group.
Results Interviewees reported being unfamiliar (43%), moderately familiar (42%), or very familiar (15%) with preference 
methods and studies. Interviewees across stakeholder groups generally supported the idea of using PP in the medical prod-
uct lifecycle but expressed mixed opinions about the feasibility and impact of using PP in decision making. Interviewees 
from all stakeholder groups stressed the importance of increasing stakeholders’ understanding of the concept of PP and 
preference methods and ensuring patients’ understanding of the questions asked in PP studies. Key concerns and needs in 
each interviewed stakeholder group were as follows: (1) academics: investigating the validity, reliability, reproducibility, 
and generalizability of preference methods; (2) health technology assessment/payer representatives: developing quality 
criteria for evaluating PP studies and gaining insights into how to weigh them in reimbursement/payer decision making; (3) 
industry representatives: obtaining guidance on PP studies and recognition on the importance of PP from decision makers; 
(4) patients, caregivers, and patient representatives: providing an incentive and adequate information towards patients when 
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participating in PP studies; (5) physicians: avoiding bias as a result of commercial agendas in PP studies and clarifying how to 
deal with subjective and emotional elements when measuring PP; and (6) regulators: avoiding the misuse of PP study results 
to overrule the traditional efficacy and safety criteria used for marketing authorization and obtaining robust PP study results.
Conclusions Despite the interest all interviewed stakeholder groups reported in PP, the effective use of PP in decision mak-
ing across the medical product lifecycle is currently hampered by a lack of standardization and consensus on how to both 
measure and use PP.
Key Points for Decision Makers 
Despite increased attention towards patient preferences 
(PP), the use of PP in medical product decision making 
remains limited and unstructured.
In this qualitative research, 143 individual interviews 
were conducted to characterize stakeholders’ attitudes, 
needs, and concerns towards PP in decision making 
along the medical product lifecycle.
To increase the use of PP, efforts are needed on three 
levels: (1) the cultural and educational level, via increas-
ing acceptance and understanding among stakeholders 
about PP; (2) the methodological level, via increasing 
understanding of quality criteria of PP studies; and (3) 
the procedural level, via increasing understanding on 
how to integrate PP in current medical product decision 
making.
1 Introduction
The role of patient preferences (PP) is being increasingly 
explored in several decision-making contexts throughout 
the life cycle of drugs and medical devices (i.e., the medi-
cal product life cycle [MPLC]) [1–3]. Different definitions, 
conceptualizations, and categorizations for PP exist. The US 
Food and Drug Administration (FDA) adopted the following 
definition for ‘patient preference information’: “qualitative 
or quantitative assessments of the relative desirability or 
acceptability to patients of specified alternatives or choices 
among outcomes or other attributes that differ among alter-
native health interventions” [3]. Others have defined PP and 
methods to investigate them in a narrower manner by solely 
referring to ‘utilities’ and quantitative ‘elicitation’ methods, 
respectively [4–9]. In this study, the terms ‘PP’ and ‘pref-
erence methods’ are used to refer to both qualitative and 
quantitative PP and preference methods, according to the 
FDA definition [3].
Decision-making stakeholders interested in PP include 
regulatory agencies responsible for the marketing authoriza-
tion of medical products, such as the European Medicines 
Agency (EMA) and the FDA, and health technology assess-
ment (HTA) bodies and reimbursement agencies responsi-
ble for HTA and the reimbursement of medical products 
[2, 10–12]. In the regulatory context, PP have been argued 
to provide insights into what benefit-risk trade-offs patients 
accept [3, 5, 13–23]. On the HTA/reimbursement level, PP 
could provide information about patients’ preferred medical 
products and clinical outcomes [6, 24–29]. Outside the regu-
latory and reimbursement context, industry stakeholders are 
exploring how PP can inform priority setting, clinical trial 
design and analysis, and post-marketing risk assessments 
[3, 7, 15, 19, 21, 30].
Reflecting these interests, decision-making bodies have 
started assessing the value of preference methods; the EMA 
investigated patient benefit-risk trade-offs for treatment out-
comes [31], and the FDA quantified PP for the treatment 
attributes of weight-loss devices. The FDA issued two guid-
ance documents about PP: recommendations for collecting 
PP in the context of medical devices and draft guidance 
for collecting patient experience data, including PP, in the 
context of drugs [3, 17, 32–35]. Examples of efforts at the 
reimbursement level include the conduct of PP studies by the 
Institute for Quality and Efficiency in Health Care1 and the 
first scientific advice on a PP study design from the National 
Institute for Health and Care Excellence2 [29, 36, 37].
Despite demonstrated interest, PP studies are currently 
not submitted and evaluated systematically during market-
ing authorization [38]. Similarly, the use of PP in HTA has 
been described to be in its infancy, and few HTA organiza-
tions have guidelines on how PP should be measured [35, 
39]. In addition, no evidence-based guidance on the design 
and conduct of PP studies is available for industry. As the 
adoption of PP depends on the stakeholders involved in the 
MPLC (academics, HTA bodies, payers, industry, patients, 
physicians, and regulators), knowledge of their perceptions 
of PP is a critical step towards increasing the use of PP. 
Moreover, as these stakeholders’ decisions depend on each 
other, implementing PP in the MPLC would impact each 
1 Scientific institute advising reimbursement decisions in Germany.
2 Consultancy service providing scientific advice to industry for 
National Institute for Health and Care Excellence evaluations and 
supporting discussions with payers and commissioners to enable mar-
ket access in the UK.
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stakeholder involved. This study therefore aimed to charac-
terize stakeholders’ perceptions of PP and, more specifically, 
their attitudes, needs, and concerns related to PP in decision 
making along the MPLC.
2  Materials and Methods
2.1  General Design
Because this study aimed to gain deeper insights into stake-
holders’ attitudes, needs, and concerns, a qualitative study 
design was chosen. In view of the geographical dispersion, 
diversity, and number of interviewees within each stake-
holder group, interviews were chosen as the data collection 
method [40]. Interviews were conducted as part of PREFER3 
between April and August 2017.
2.2  Interviewee Selection
Interviewees were recruited from six different stakeholder 
groups to account for the diversity of stakeholders involved 
in the MPLC. Interviewees were recruited from eight coun-
tries to obtain insights from stakeholders familiar with dif-
ferent healthcare systems. Patients, caregivers, physicians, 
and patient organization representatives were recruited from 
four disease areas4 to increase the heterogeneity of the sam-
ple in terms of disease types. To further ensure a heterogene-
ous sample, inclusion criteria and quota were set (Electronic 
Supplementary Material [ESM] 1). An initial sample was 
established through suggestions from PREFER consor-
tium members. From these suggestions, 22 persons met the 
inclusion criteria and were invited to participate via e-mail. 
Twelve persons (55%) accepted; the others did not answer, 
did not consider themselves knowledgeable enough, or did 
not have time. Subsequent interviewees were suggested by 
interviewed persons (snowballing). Recruitment was slow-
est in Romania and Italy and in the HTA and regulatory 
stakeholder group.5 No relationship between interviewers 
and interviewees was established prior to invitation.
2.3  Interview Guide
The interview guide was developed based upon the research 
aims, 16 exploratory interviews, and a literature review 
(Table 1, ESM 2). Exploratory interviews were conducted 
with HTA/payer representatives (n = 4), regulators (n = 2), 
industry representatives (n = 3), patient organization rep-
resentatives (n = 4), physicians (n = 2), and one academic 
(n = 1). The literature review identified the opportunities and 
challenges associated with PP (Janssens et al., submitted, 
2019). One version of the interview guide was developed for 
HTA/payer representatives, regulators, industry representa-
tives, and academics and one version for patients, patient 
organization representatives, caregivers, and physicians. 
The latter version was shorter, used simpler terminology, 
included more comprehensive information parts, and did not 
address the more methodological topics (Table 1). Both ver-
sions were reviewed and pilot tested with five interviewees 
of the targeted stakeholder groups.
2.4  Data Collection
An interview protocol was developed and discussed with 
eight interviewers (RJ, SR, EvO, CW, KSB, AC, ME, RD)6 
as a form of training for conducting the interviews and to 
minimize variability across interviews (ESM 3). A glossary 
was sent to patients, patient organization representatives, 
caregivers, and physicians prior to the interview (ESM 4). 
At the start of the semi-structured7 interview, interviewers 
presented themselves and explained the aim of the PRE-
FER project and interview. Interviews with patients, patient 
organization representatives, caregivers, and physicians 
were conducted in their native language. Other interviews 
were conducted in English unless preferred otherwise by 
the interviewee. Interviews took approximately 1 hour and 
were conducted via telephone or face to face, the latter at 
a location preferred by the interviewee. In addition to the 
interviewer and interviewee, no one was present during the 
3 A 5-year project that received funding from the Innovative Medi-
cines Initiative 2 Joint Undertaking. PREFER aims to establish rec-
ommendations to guide industry, regulatory authorities, and HTA/
reimbursement bodies on how and when to include PP.
4 Lung cancer, rheumatoid arthritis, myotonic dystrophy type 1, and 
cardiovascular disease were selected to include diseases varying in 
prevalence and chronicity.
5 The median interview date occurred at the latest time point in Italy 
and Romania. The final interviews took place with HTA body and 
regulatory interviewees.
6 RJ, EvO, CW, and KSB are PhD researchers with backgrounds in 
biomedical sciences (RJ, EvO), global health (CW), and public health 
(KSB). SR is a post-doctoral researcher with a background in health 
and cognitive psychology and trained in qualitative research meth-
ods. AC is the founder of Community Health Association Romania. 
ME is a data scientist with a background in psychology. RD is a sen-
ior director of benefit-risk and epidemiology at Janssen Research & 
Development.
7 The interview guide included fixed questions, obligatory to address 
in the interview, and questions to be asked if interviewees were famil-
iar with preference methods and studies. Per question, additional 
questions could be asked for further explanation, for confirmation or 
for more in-depth answers from interviewees.
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interview. Interviews were audio-recorded. One interview 
was conducted per interviewee.8
2.5  Data Analysis
Interviews were analyzed thematically by two researchers 
(RJ, SR). The framework method was chosen for analysis, as 
it enables multiple researchers to independently analyse one 
large dataset [41, 42]. Table 2 explains the implementation 
of the seven stages of the framework method: transcription, 
familiarization, coding, developing an analytical framework, 
applying the analytical framework, charting, and interpret-
ing. Open answers to the question asking about interview-
ees’ familiarity with PP were categorized into “not familiar”, 
“moderately familiar”, or “very familiar” and were analyzed 
descriptively in Excel.
3  Results
The results section is structured according to the themes 
identified during analysis. Key findings per stakeholder 
group are visualized in Fig. 1.
3.1  Interviewees’ Characteristics
One hundred and forty-three persons participated. Interview-
ees reported being unfamiliar (43%), moderately familiar 
(42%), or very familiar (15%) with preference methods and 
studies (Table 3). Self-reported familiarity was highest in 
academics, among whom 50% reported being very famil-
iar, and it was the lowest in patients and physicians, among 
whom 86% and 75%, respectively, reported being unfamiliar 
with PP (ESM 7).
3.2  Definition of Patient Preferences (PP) 
and Awareness
3.2.1  Defining ‘PP’
When interviewees were asked about their personal defi-
nition for PP, interviewees from all stakeholder groups 
underlined the challenge of providing such a definition. 
Whereas academics more often used a focused definition 
(e.g., trade-offs between treatment outcomes), interviewees 
from the other stakeholder groups most frequently adopted 
a broad definition (e.g., patients’ perspectives) (Fig. 1). An 
academic and regulator explained how the lack of an agreed-
upon definition causes confusion: “Well, I think it is a term 
that is being used in a number of different ways, and I think 
it would be beneficial if a definition can be agreed upon, just 
to reduce confusion” (RE_US_6).9
Table 1  Topics addressed in the 
interview
For the complete interview guide, see Electronic Supplementary Material 2
FDA US Food and Drug Administration, MPLC medical product life cycle, PP patient preferences
a A simplified version of the FDA definition was presented to patients, patient organization representatives, 
caregivers, and physicians
b Topics not discussed with patients, patient organization representatives, caregivers, and physicians
1. Definition for PP
 (a) Personal definition for PP
 (b) FDA  definitiona
2. Familiarity and experience with preference methods and PP studies
3. Importance and role for PP in the MPLC
 (a) Reasons why PP should (not) be used
 (b) Stages and decisions in the MPLC PP where PP should (not) play a role
4. Needs for implementing PP in decisions and aspects that are lacking now
 (a) Approach for conducting PP  studiesb
 (b) Type of sample when conducting PP studies
 (c) Methodological requirements when conducting PP  studiesb
 (d) Quality criteria for evaluating PP  studiesb
5. Concerns related to PP
 (a) Heterogeneity of the patient  sampleb
6. Impact or change when using PP
8 Repeat interviews were not performed.
9 Quotations are coded as follows: abbreviation of stakeholder group, 
country, and ID number. Abbreviations for the stakeholder groups 
are as follows: PA  patients, PO  patient organization representatives, 
CA  caregivers, IN  industry representatives, RE  regulators, PY HTA/
payer representatives, PH physicians, AC academics.
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3.2.2  Awareness and Acceptance
Interviewees from all stakeholders mentioned a need for 
higher understanding of the concept of PP and preference 
methods. In this context, some academics and regulators 
called for training opportunities for decision makers and 
researchers. Several patient organization representatives, 
academics, and industry representatives mentioned that 
more acceptance of the concept of PP is needed: “A kind of 
general alignment of what patient preferences are, why they 
are important and why they need to be included in the drug 
development pathway” (AC_IT_24).
Table 2  Stages of the framework method
Steps followed for the analysis of the interviews
1. Transcription The audio-recordings were transcribed verbatim. Transcripts were not returned to interviewees 
for comments and/or corrections, except upon explicit request by the interviewee. Interviews 
were transcribed in the original language, and if necessary, translated to English
2. Familiarization RJ and SR thoroughly read and re-read each transcript and listened back to the audio-recorded 
interviews whenever a certain part of the transcript was unclear. The margins of the transcripts 
were used to write down analytical notes, thoughts, or impressions (e.g., when interviewees 
expressed exceptionally strong or contrasting views to other interviewees)
3. Coding Based upon pre-defined sets of interests to the research, the research questions and questions in 
the interview guide, RJ and SR developed a pre-defined coding list and a brief definition for 
each of the codes (Electronic Supplementary Material 5, coding list 1). RJ and SR indepen-
dently coded the first available 6 transcripts from 6 interviewees belonging to the 6 different 
stakeholder groups, using the predefined codes, to assess whether all relevant topics could be 
assigned a code. If a certain topic was not covered with the pre-defined coding list, a new code 
was assigned (open coding)
4. Developing a working analytical framework RJ and SR discussed the codes they assigned to each passage. They discussed why they coded it, 
i.e., why they perceived it as meaningful to answer the research questions. After the discus-
sion, RJ and SR agreed on an adapted set of codes. RJ and SR then independently coded 6 
more transcripts, using the adapted coding list, taking care to note any new codes or impres-
sions that did not fit the existing set. RJ and SR then met again and evaluated the coding list to 
incorporate new codes or rename codes. At this point RJ and SR also decided whether certain 
codes were related and if so, whether they could be grouped
5. Applying the analytical framework The list of codes was uploaded in NVivo (11th edition, QSR International). The transcripts were 
divided equally among RJ and SR. Using NVivo, SR and RJ went through each transcript and 
highlighted passages of text and selected and attached an appropriate code from the coding 
list (coding). During coding, SR and RJ regularly discussed to refine the coding list until no 
changes were necessary (i.e., when coding saturation was reached and the final coding list was 
established). The coding list consisted of codes and sub-codes, each with a brief explanatory 
description of their meaning and examples of what ideas or elements could be summarized 
under that code (Electronic Supplementary Material 5, coding list 2)
6. Charting the data into the framework matrix Excel was used for charting (summarizing) the data. RJ and SR exported the coded text per code 
from the final list of codes, from NVivo to Excel. In Excel, a separate tab sheet was created 
per ‘overarching’ code (Electronic Supplementary Material 6). Each tab sheet comprised one 
row per interviewee and one column per sub-code. To allow for within- and across-stakeholder 
group comparisons, the interviewees from the same stakeholder group were placed next to 
each other. SR and RJ each charted half of the transcripts. To retain links to the transcripts, 
verbatim text was indicated by underlining it. RJ and SR held regular meetings to compare 
their charting approaches and to ensure consistency in their approaches
7. Mapping and interpretation The development of themes was done both deductively (i.e., influenced by the research ques-
tions) and inductively (i.e., influenced by new codes generated inductively from the data). 
The framework matrix in Excel was analyzed qualitatively so that relevant statements could 
emerge even if only mentioned a few times by interviewees. In a stepwise manner, RJ and SR: 
(1) independently wrote down their interpretations for each overarching code and stakeholder 
group and (2) convened to discuss their interpretations per overarching code and stakeholder 
group (investigators’ triangulation). During these discussions, RJ and SR reached a consensus 
about stakeholder groups’ priorities regarding PP and subsequently derived the statements in 
Fig. 1. RJ and SR also discussed potential themes and reached a consensus about these themes. 
Whenever the data were rich enough, the interpretations generated in this stage went beyond 
the description of a particular interviewee to the explanation of potential reasons or beliefs of 
multiple interviewees. Participants were not asked to provide feedback on the results
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3.3  Attitudes Towards PP, Their Value and Impact 
on Decision Making
3.3.1  Interviewees’ Attitudes Towards PP
The majority of interviewees across stakeholder groups were 
positive towards using PP in the MPLC, as patients are final 
healthcare users, have disease experience, and the use of PP 
could improve decision making (see Sect. 3.3.3). Whereas 
industry interviewees seemed most positive towards PP, phy-
sicians most frequently were hesitant towards using PP or 
against using PP. Interviewees who doubted the value and 
use of PP made the following arguments:
• Patients lack scientific knowledge (AC, IN, PA, CA, PH, 
RE; see Sect. 3.4.2);
• Patients have unrealistic preferences and are not objective 
enough (PH);
• Preference methods are of low quality (PY, RE, AC, see 
Sect. 3.4.5);
• PP do not fit in current decision-making processes (PH, 
AC, PY, see Sect. 3.5.1);
• Using PP would not alter the decision (PH, AC, see 
Sect. 3.3.2); and
• In the context of reimbursement, societal preferences 
rather than patient preferences should be used (PY, see 
Sect. 3.4.3) (Fig. 1).
3.3.2  Value of PP is Context Dependent
Interviewees from all stakeholder groups, particularly regu-
lators, underlined that the value of PP in decision making 
depends on factors such as the type of medical product and 
Key concerns and needs
Patients • Including all relevant stakeholders in PP study design
• Adequately informing paents about PP study
• Incenvizing paents to parcipate in PP studies
• Disclosure of PP study results towards parcipants
• Remaining PP study results confidenal
67% unfamiliar 
Defined PP as paent perspecves, 
desires and what paents find 
important
Academics • Be er methodological characterizaon of PP methods  
• Clear methodological standards and guidance for PP studies
• A good PP study design: right a ributes and levels, no bias 
• Transparent reporng of PP study design and results
50% very familiar 
Defined PP as paent choices, trade-
offs, values and priories
Physicians • Lack of paents’ scienfic knowledge
• Risk of bias in PP studies due to industry’s commercially driven agenda 
• Clarifying how to deal with emoonal and subjecve influences on PP
• Superiority of tradional efficacy criteria in decision-making
75% unfamiliar
Defined PP as individual 
treatment choices
• Value of PP depends on benefit-risk balance, product and disease area
• Scienfically strong methods yielding robust and unbiased PP study results
• Elicing PP from paents who are informed and free of conflicng interests
• Considering PP together with other evidence in markeng authorizaon
• Misuse of PP to circumvent normal regulatory process
Regulators
57% moderately familiar
Defined PP as paent perspecves, 
feelings, percepons and 
expectaons
HTA&
Payers
• More confidence in PP methods
• Consensus on use of societal versus paent preferences
• Idenfying quality criteria for evaluang PP studies
• More clarity on how to integrate PP in decision-making frameworks
• Avoiding use of PP to create disparies between disease areas
67% moderately familiar
Defined PP as what paents want 
and value 
Familiarity and definition
Industry
46% moderately familiar
Defined PP as paent perspecves, 
needs, feelings and choices
• Clear recognion of PP by decision-makers
• More certainty regarding PP study investments
• Clear (regulatory) guidance on how to conduct PP studies
• More methodological standardizaon
• Dealing with unexpected PP study results
Fig. 1  Stakeholders’ perceptions about patient preferences (PP). Left: 
interviewees’ self-reported familiarity with PP studies and methods 
and how they defined PP. Right: stakeholders’ key needs and con-
cerns related to PP in decision making along the medical product life 
cycle. The patient group includes patients, caregivers, and patient 
organization representatives
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disease area (Fig. 1). Furthermore, some academics and 
regulators stated that PP studies only need to be conducted 
when they are relevant for decision making.
3.3.3  Impact of PP on Decision Making
There were diverging views regarding the impact of PP on 
decisions. Interviewees from different stakeholder groups 
(AC, PY, PA, IN) underlined that it would take a long 
time before PP would become part of the regular decision-
making system because of the complexity of doing so (see 
Sect. 3.5.1).
Regarding development, interviewees from different 
stakeholder groups described the impact as follows:
• Better industry investments (PA, PY, RE);
• Enhanced patient recruitment into clinical trials (PA);
• Increased development of medical products that meet 
patient needs (AC, PY, IN, PH, RE, PO);
• Easier or faster market access (RE, IN); and
• Higher acceptance of the drug among patients (IN, PH, 
PO, RE, AC).
Regarding the impact on marketing authorization and 
HTA/reimbursement, some HTA/payers, industry repre-
sentatives, and regulators predicted the following:
• A higher external acceptance of decisions (IN, RE);
• A positive change in the decision makers’ approach to 
benefit-risk assessments (RE): “A dramatic change in the 
concern of regulators […], it would become normal when 
discussing the benefits and risks” (RE_UK_11);
• A price increase (PY): “If medical products have attrib-
utes that patients value, then presumably manufacturers 
will charge more for those products” (PY_SE_14);
• Higher quality decisions (RE, PY, IN) by increasing cer-
tainty for decision makers when there are uncertainties 
regarding the clinical evidence; and
• More decisions are made (PY): “Now some decisions 
[…] just can’t be made simply because they don’t have 
the proper data” (PY_DE_8).
Regarding the impact of PP on decision outcomes, dif-
ferent opinions were expressed. With respect to marketing 
authorization, several interviewees (IN, AC, PY, RE) fore-
saw a marginal effect: “If you already approve 90% of all 
treatments, then you cannot really make that much of an 
impact” (AC_NL_12). One regulator explained that spe-
cifically in cases in which there is a clear benefit-risk bal-
ance, the decision outcome would not necessarily change 
if PP were considered. On the HTA/reimbursement level, 
some HTA/payers and industry representatives stated that 
the use of PP would lead to different decisions being made 
“due to the system we have here currently (…) it says that 
only patient relevant endpoints are considered. However, 
patients were never asked what patient-relevant end-points 
are” (IN_DE_10).
3.4  Concerns and Needs Regarding Measuring PP 
for Decision Making
3.4.1  Guiding Framework for Measuring PP
Several academics and industry representatives expressed 
concerns about a lack of consensus on how to measure PP 
Table 3  Interviewees’ characteristics
For demographics per stakeholder group, country, and disease area, 
see Electronic Supplementary Material 7
HTA health technology assessment, PP patient preferences
a Persons with anticipated knowledge on patient involvement or pref-
erence methods and working in an academic or research institution
b Persons formally involved in HTA or reimbursement
c Persons working in or providing consultancy to drug or medical 
device companies
d Diagnosed with, associated with, or providing care to patients in the 
following disease areas: lung cancer, rheumatoid arthritis, myotonic 
dystrophy type 1, cardiovascular diseases
e Persons with a formal role in national or European marketing author-
ization
Characteristics Interviewees 
(n = 143)
n %
Country
 Italy 24 17
 Romania 23 16
 Sweden 24 17
 UK 24 17
 France 12 8
 Germany 12 8
 The Netherlands 12 8
 USA 12 8
Stakeholder group
 Academica 24 17
 HTA/payer  representativeb 24 17
 Industry  representativec 24 17
 Patientd 14 10
 Patient organization  representatived 8 6
 Caregiverd 2 1
 Physiciand 24 17
 Regulatore 23 16
Self-reported familiarity with  PPf
 Not familiar 61 43
 Moderately familiar 60 42
 Very familiar 22 15
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and, more specifically, how to select the following: (1) a 
sample (see Sect. 3.4.3); (2) a preference method; (3) attrib-
utes and levels; and (4) the stage in the MPLC to conduct a 
preference study. Several of them elaborated on how more 
standardization, guidance, and best practices would demon-
strate the manner in which PP studies should be undertaken. 
Some of them argued that standardization could be achieved 
through regulatory guidance, a change in legislation, or a 
clearer regulatory framework: “Some rules, clearly defined, 
telling you in what process you involve the patients, how 
representative they should be (…) and so on” (AC_RO_22). 
Some industry interviewees explained that a regulatory 
framework would provide them with more certainty to 
invest in a preference study: “Every study needs invest-
ment when the clinical development of a drug is a costly 
process, where we have to make choices” (IN_IT_18). 
Some academics underlined, however, the difficulty of for-
malizing preference research and argued that developing 
strict guidance would stop preference research: “It is very 
risky to have to sit down and write rules about how to do 
things involving research” (AC_US_12). Similarly, there 
were mixed views on the level of detail this guidance should 
have; whereas one academic highlighted that existing guide-
lines “are probably too basic” (AC_UK_21), another aca-
demic and industry representative elaborated that this guid-
ance should be flexible so that “according to the specific 
context, you are free to choose which one (method) is most 
suitable” (AC_IT_21). Several academics and HTA/payer 
interviewees particularly described how a checklist of qual-
ity criteria would be useful, and some academics mentioned 
that more research on how to rate the quality of PP studies 
and their outcomes would help in the construction of such 
a checklist.
3.4.2  Patient Knowledge and Education
Interviewees from all stakeholder groups described the cur-
rent level of patient knowledge as a concern for the meas-
urement and use of PP in decision making. One patient 
attributed the lack of knowledge to the lack of information 
given to patients about the preference study. In addition to 
knowledge about the preference study, interviewees from 
all stakeholder groups also referred to patients’ educational 
level and knowledge about the MPLC and about the medical 
product. To increase patient understanding, some patients 
advocated for the inclusion of an educational component in 
PP studies. Interviewees from all stakeholder groups were 
concerned about the complexity of questions in PP studies. 
Some regulators and academics underlined how a lack of 
understanding among participants decreases the reliabil-
ity of the preference study results and advocated for more 
research verifying whether patients actually understood the 
questions.
3.4.3  Sample
Interviewees from all stakeholder groups, except patients 
and physicians, raised a need for clarifying what would be 
the “ideal” sample in terms of the size, heterogeneity, and 
type of participants that would ensure the usefulness of the 
study results for decision making: “Should it be European, 
Nordic, American, Asian? (…) I mean, there are a number 
of questions like these that you have to sit down and decide” 
(IN_SE_17). Some academics and HTA/payer representa-
tives specifically raised the question of using societal vs. 
patient preferences to guide reimbursement decisions: “I 
think I personally would have a preference for doing public 
so - I feel like preferences are important, it’s just whose 
preferences that I’m worried about” (UK_AC_21). The con-
cept of ‘heterogeneity’, both of the patient sample and of 
the measured preferences, triggered diverging views across 
academics, regulators, HTA/reimbursement, and industry 
representatives. Some of them considered heterogeneity to 
be a desirable element. Others were concerned about prefer-
ence heterogeneity being present but not being measured or 
reported transparently. Finally, some considered heterogene-
ity to be both negative and positive: “It’s true; we have to do 
a better job, we have to explain heterogeneity, I think it will 
be positive in the future because that could actually lead to 
a more personalised approach to treatments” (AC_DE_11).
3.4.4  Factors Influencing PP Study Results
Several academics, physicians, and regulators described 
factors that may influence PP: sociocultural status, emo-
tions, time, media, psychological factors, and disease status. 
They reasoned that the impact of these factors on PP study 
results is often unknown to researchers. One regulator was 
concerned about how the sole act of measuring PP might 
impact preferences of participants: “If I obtain the patient’s 
preference, the problem is understanding what I have really 
obtained (…) I have also directed this preference invol-
untary” (RE_IT_11). Interviewees across all stakeholder 
groups were apprehensive about methodological choices 
in the design of PP studies (e.g., question framing, select-
ing certain patient groups), leading to biased results, and 
several mentioned the risk that pharmaceutical companies 
would want to use these results to “persuade the regulator 
of something that is actually quite potentially dangerous” 
(RE_US_6).
3.4.5  Scientifically Robust Preference Methods
Interviewees from all stakeholder groups except patients, 
caregivers, and patient organization representatives indi-
cated a current lack of methodological understanding 
related to the available methods for measuring PP. Some of 
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them considered the preference research field to be “not a 
very well-developed area of research” (UK_PY_15). More 
specifically, interviewees across these stakeholder groups 
expressed doubts about the validity, reliability, reproduc-
ibility, and generalizability of preference methods and 
results. Some of these interviewees reasoned that not know-
ing how preference methods perform on these criteria low-
ers their usefulness for decision making: “We know little 
about the reliability, the reproducibility, etc. (…) It (prefer-
ence research) has little weight on policy decision making 
because of those reasons” (AC_FR_11).
Several academics, regulators, and HTA/payer and indus-
try representatives stressed the need for more research that 
validates different preference methods. However, only a few 
suggested specific study designs to better characterize pref-
erence methods: “Different types of methods in the same 
patient population and this type of information I think we 
need” (RE_NL_6). Furthermore, while methods need to 
be “scientifically credible” (IN_DE_9), some industry and 
academic interviewees raised a need for simpler methods 
because (1) “many of these questions come up on a very 
time critical path” and (2) complex methods are “cognitively 
burdensome” (AC_IT_21).
3.4.6  Multi‑Stakeholder Approach
Some patient organization representatives and regulators 
underlined how relevant stakeholder groups (e.g., spon-
sors, patients, caregivers, regulatory agencies) need to be 
involved in the design and conduct of PP studies to increase 
their value for decision making. For example, collaboration 
between researchers and regulators was described as useful 
because scientists have preference research expertise and 
regulators can “determine whether PP information would 
be useful to answer certain regulatory decision questions” 
(US_RE_5).
3.5  Concerns and Needs Regarding the Use of PP 
in Decision Making
3.5.1  Integrating PP in Decision Making
Interviewees from all stakeholder groups except patients, 
caregivers, and patient organization representatives ques-
tioned the feasibility and lack of a clear strategy for includ-
ing PP in current development, marketing authorization, and 
reimbursement decisions. Several HTA/payers, industry rep-
resentatives, and academics questioned how PP should be 
weighted in decisions. These stakeholder groups but also 
particularly regulators underlined that PP should be con-
sidered together with other evidence. Similarly, regulators 
and physicians stated that PP should not completely guide 
the decision, as they perceived other “traditional” criteria 
(e.g., efficacy, safety) to be more important. To be useful for 
marketing authorization, one US regulator underlined that 
regulators need to be able to link the preference study results 
to the clinical trial outcomes of the medical product under 
review. Similarly, one HTA/payer representative raised 
the need for a “consistent approach of measuring patient 
preferences in different indications so that they can be very 
directly translatable to decision making” (HT_NL_8).
3.5.2  Framework for Using PP
There were diverging views regarding what specifically is 
needed to integrate PP into decision making. While sev-
eral academics, regulators, payers, and patient organization 
interviewees felt that PP should be integrated based on a 
framework that allows for the transparent use of PP in deci-
sion making, another academic argued to “just use this as 
a source of information, and they will come up with deci-
sions” (AC_DE_11).
3.5.3  Handling Preference Study Results
Several regulators, academics, and physicians emphasized 
that the submission of PP studies to decision makers needs 
to be transparent. More specifically, they argued how all par-
ticipant variables as well as all the preference study results 
need to be reported to avoid the selective reporting of results. 
One industry representative raised the question of dealing 
with unexpected results: “But what if (…) it doesn’t really 
fit in our advantage; how will we deal with it?” (IN_NL_10). 
Some patients and patient organization representatives raised 
the issue of confidentiality of patient information: “Getting 
access to your name and identity, and that whole thing, or 
someone sending a bulk email” (PA_SE_1). One caregiver 
mentioned the need to disclose preference study outcomes 
to patients.
3.5.4  Misuse of PP in Decision Making and Creating 
Disparities
Several regulators, academics, and HTA/payer representa-
tives expressed concerns about the risk of misusing PP 
in decision making “to overcome other important aspects 
of the technology” (AC_IT_24) or “to make more profit” 
(PY_IT_13). Two HTA/payer representatives further pro-
posed that the risk of misusing PP to force decision mak-
ers towards a certain decision outcome should be mitigated 
when embarking on preference research: “I am concerned 
that there will be (…) a huge amount of so-called preference 
studies that will be used to say ‘Oh, you say, the patient 
said that so you have to act’” (PY_IT_13). In the context 
of marketing authorization, some regulators described the 
risk that pharmaceutical companies could misuse PP to 
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“circumvent the normal regulatory process” (RE_UK_9). 
Two HTA/payer representatives were concerned about dis-
parities generated by PP being central for regulatory and 
HTA decision making as more influential advocacy groups 
may have a more central political role: “It favours that group 
of patients for the sole reason that they prefer it that way and 
they’ve been able to influence because of they have a very 
strong patient organization” (PY_SE_14).
4  Discussion
This study provides insights into stakeholders’ attitudes, 
needs, and concerns related to PP in decision making 
along the MPLC. Interviewees from all stakeholder groups 
stressed the importance of increasing stakeholders’ under-
standing of the concept of PP and preference methods and 
ensuring patients’ understanding of the questions asked in 
PP studies. Key concerns and needs per stakeholder group 
included the following (Fig. 1):
• Academics: researching the validity, reliability, reproduc-
ibility, and generalizability of preference methods;
• HTA/payer representatives: developing quality criteria 
for evaluating PP studies and gaining insights into how 
to weigh PP study results in decision making;
• Industry representatives: obtaining guidance on the 
design and conduct of PP studies and recognition on the 
importance of PP from decision makers;
• Patients, caregivers, and patient representatives: provid-
ing incentive and adequate information towards patients 
when participating in PP studies;
• Physicians: avoiding bias due to commercial agendas in 
PP studies and clarifying how to address subjective and 
emotional elements when measuring PP; and
• Regulators: avoiding the misuse of PP study results to 
overrule the traditional efficacy and safety criteria for 
marketing authorization and obtaining robust PP study 
results.
This study underpins the importance of educating stake-
holders about the concept of PP and preference methods; 
43% of interviewees reported not being familiar with PP, and 
interviewees from all stakeholder groups raised the need for 
higher awareness among stakeholders (decision makers, cli-
nicians, academics, and patients) on PP studies. Examples of 
efforts to increase familiarity among stakeholders are accu-
mulating, e.g., webinars by the FDA and congresses about 
health preference research [43, 44]. This study also points 
towards a critical need for a framework to measure PP more 
structurally. Such efforts are also ongoing, e.g., the issuance 
of draft guidance by the FDA for collecting and submitting 
patient experience data (including PP) [33].
Interviewees raised several methodological questions 
(e.g., about the sample and the validity of PP study results), 
some of which are touched upon in regulatory guidance [3] 
already available from before the initiation of this study. 
This finding could imply that interviewees were unaware 
of this guidance and/or that more research on these topics 
is needed because the existing guidance is not sufficiently 
detailed. The former implication might be explained by a 
lack of guidance in the European context; thus far, there is 
no guidance from the EMA on how to measure PP for regu-
latory purposes. The second implication has also been raised 
by Johnson et al. [45], stating that available FDA guidance 
“provides little help for readers in assessing the relevance of 
the listed methods for FDA regulatory reviews”. Regarding 
method selection, the present study reveals tension related to 
the desired level of robustness of preference methods; while 
interviewees from several stakeholder groups found it cru-
cial that preference methods are scientifically robust, some 
interviewees argued that “simpler” methods are necessary 
to reduce the cognitive burden of the method and to reduce 
the cost and time needed to conduct the preference study. 
The FDA guidance [3] states that “newer methods may also 
be acceptable” but does not explicitly mention what their 
quality criteria would be.
Both on the HTA/reimbursement and marketing authori-
zation level, some interviewees argued that using PP could 
improve the quality of decision making by increasing cer-
tainty for decision makers when they need to evaluate uncer-
tain clinical evidence. Examples that reflect the interest of 
HTA bodies are the Institute for Quality and Efficiency in 
Health Care PP studies and the report by the Belgian Health 
Care Knowledge Centre10 on how to involve patients and the 
public in reimbursement and resource allocation decisions 
[2, 29, 36]. However, no formal guidance has been issued by 
HTA bodies or reimbursement decision makers, which might 
explain the uncertainty expressed by interviewees on how to 
conduct PP studies for HTA and reimbursement.
As suggested by some regulators in this study and 
reflected in a recent example in which the National Institute 
for Health and Care Excellence provided scientific advice 
[37], gathering input from decision makers on specific PP 
study designs may be an important step forward. Based on 
their experience, the National Institute for Health and Care 
Excellence recommends that companies seek their advice on 
PP study designs to allow for the PP study results to be used 
in clinical development programs for new treatments. Such 
advice may be both valuable from the company’s perspective 
to ensure that PP study results will be useful for decision 
makers as well as from the decision makers’ perspective to 
10 Scientific institute advising reimbursement decisions in Belgium.
523Stakeholder Perceptions about Patient Preferences in the Medical Product Life Cycle
ensure that potential methodological issues are addressed 
prior to conducting the PP study.
The main strength of this study is its inclusiveness; inter-
viewees were equally recruited from six different stakeholder 
groups and eight countries, resulting in a heterogeneous and 
large sample. However, the magnitude of this study can also 
be viewed as a limitation because it precluded gaining in-
depth insights into the motivations and background of each 
interviewee. We captured the country, stakeholder group, 
and familiarity of interviewees but did not differentiate 
results according to other interviewee characteristics. For 
example, their opinions may also be shaped by the type of 
preference method they were most familiar with.
It is important to interpret the results in light of inter-
viewees’ knowledge of the topic; interviewees reported 
being unfamiliar (43%), moderately familiar (42%), or very 
familiar (15%) with preference methods and studies. Self-
reported familiarity was highest among academics and low-
est among patients and physicians. We tried to account for a 
lower familiarity among these latter stakeholder groups by 
developing a simpler version of the interview guide for these 
stakeholder groups. Nonetheless, interviewees’ opinions 
were most likely influenced by their familiarity regarding 
the topic. For example, the stakeholder groups least familiar 
with PP studies may also be the individuals least positive 
about using PP study results in decisions. Second, interview-
ees were recruited upon suggestion by PREFER members 
and by interviewed persons. This might have resulted in a 
biased sample because these persons may be more positive 
about PP. The opinions presented in this paper should there-
fore not be interpreted as representative of a larger popula-
tion than the interviewed sample; there may very well be 
persons within each stakeholder group with views other than 
those presented in the paper.
Additionally, four interviewees per stakeholder group 
from each country do not enable comparison across all 
possible permutations of relevant interviewees’ features 
(country, stakeholder group, disease area). There were eight 
interviewers with likely different interviewing styles. How-
ever, having eight interviewers was necessary to conduct 
interviews in some interviewees’ native language. We tried 
to minimize differences in interviewing styles by using an 
interviewing protocol and organizing an explanatory proto-
col meeting. All but one interviewer (AC) were part of the 
PREFER project. Although interviewers had no personal 
interest in the study outcome, their knowledge and assump-
tions about the research topic may have shaped the direction 
of the interviews. A final limitation relates to terminology; 
after interviewees’ personal definitions of PP were elicited, 
a definition of PP was provided at the beginning of the inter-
view. Nevertheless, interviewees might have referred to their 
own pre-existing definitions during the interview.
5  Conclusions
Despite interest from interviewees within each of the stake-
holder groups, an effective use of PP is hampered by a lack 
of standardization and consensus on how to measure PP and 
use PP in decision making. To advance usage of PP, efforts 
are needed on three levels that mirror stakeholders’ needs 
and concerns: (1) the educational and cultural level, via 
increased awareness and understanding among stakeholders 
about concept of PP, preference methods and the potential 
value of using PP in decision making; (2) the methodologi-
cal level, via increased understanding of quality criteria of 
PP studies; and (3) the procedural level, via increased under-
standing on how to integrate PP into decision making.
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